December 3, 2018
- Apellis Pharmaceuticals Presents New Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at ASH
December 2, 2018
- Apellis Pharmaceuticals Presents Updated Data from a Clinical Study of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria at ASH
November 20, 2018
- Apellis Pharmaceuticals Expands Leadership Team, Appoints Adam Townsend as Chief Commercial Officer
November 13, 2018
- Apellis Pharmaceuticals Reports Third Quarter 2018 Business Update and Financial Results
November 7, 2018
- Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
November 1, 2018
- Apellis Pharmaceuticals Announces Poster Presentations at the American Society of Hematology Annual Meeting
September 28, 2018
- Apellis Pharmaceuticals to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
September 12, 2018
- Apellis Pharmaceuticals Announces First Patient Dosed in Its Phase 3 Clinical Program for APL-2 in Patients With Geographic Atrophy
September 4, 2018
- Apellis Pharmaceuticals Announces that All Four Severely Anemic Soliris™-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria in Ongoing Phase 1b Trial Have Been Transitioned to APL-2 Monotherapy
July 31, 2018
- Apellis Pharmaceuticals Reports Second Quarter 2018 Business Update and Financial Results
Displaying 1 - 10 of 41 results